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Abstract: Iridium-192 is widely used for high-dose rate brachytherapy. Co-60 source with similar geometric and dosimetric properties 
are now available. It has a longer half life but higher energy than Iridium-192. If Co-60 source can produce similar results, it will be 
more economical for low resource settings.
Objective: To evaluate the acute gastrointestinal and genitourinary toxicity associated with Co-60 source in the brachytherapy of 
  cervical cancer.
Methods: Seventy patients with cervical cancer received 45 Gy in 22 fractions of pelvic external beam radiotherapy and 19.5 Gy 
in 3 fractions of HDR with Co-60 source using tandem and ring applicators with 6 courses of cisplatin 50 mg/m2 and 5 fluorouracil 
1000 mg/m2
Results: The median total BED (Gy10) for tumor was 86.2 (84.4–88.8) while that for rectum (BED Gy3) was 124.4 (120–133). Two patients 
(3%) had grade 3 gastrointestinal toxicity while all others had #grade 2 toxicity and this is comparable with previous results.
Conclusion: Co-60 as HDR brachytherapy source is tolerable and is economical for low resource settings.
Keywords: HDR brachytherapy, Co-60 source, cervical cancer, acute toxicity
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Introduction
Cancer of the uterine cervix is one of the   malignancies 
that have been effectively treated with radiotherapy. 
A  combination  of  external  beam  treatment  with 
brachytherapy  is  used  to  increase  the  dose  to  the 
tumor with reduced dose to the organs at risk. High 
Dose  Rate  (HDR)  brachytherapy  is  now  accepted 
for cervical cancer treatment. One of its advantages 
over Low Dose Rate (LDR) treatment is the possibil-
ity to treat more patients which is better in centers 
with large turn out of patients but with limited facili-
ties such as in low resource countries like Nigeria.
Iridium 192 (Ir-192) radionuclide source is widely 
used for HDR brachytherapy. This is because it was 
easier to manufacture iridium-192 in smaller size for 
brachytherapy applications.
Cobalt-60 (Co-60) HDR source was available but 
unpopular because the earlier source sizes were larger 
than Ir-192.1 It is now possible to produce miniatur-
ized size of Co-60 radionuclide for HDR applications. 
This has been shown to have identical geometric and 
dosimetric properties with Ir-192.2
The  advantage  of  Co-60  over  Ir-192  is  its  lon-
ger half life of 5.2 years compared with 73.8 days 
for Ir-192. This implies that instead of changing the 
Ir-192 source every 3–4 months, Co-60 source can 
be changed every 6–8 years, which is a lot more eco-
nomical and attractive for low resource settings. On 
the other hand, the higher energy of 1.25 MeV of 
Co-60 compared with 0.6 MeV for Ir-192 raises con-
cerns of possible increase in toxicity to patients. This 
study was therefore carried out to assess the acute gas-
tro intestinal and genito-urinary toxicity associated 
with Co-60 as HDR source compared with published 
results in patients with cancer of the uterine cervix 
with similar characteristics, treated with Ir-192 HDR 
brachytherapy. Acute toxicity are acute reactions fol-
lowing treatment and are rapid in onset and typically 
reversible. These occur from day 1 of commencement 
of therapy to day 90 according to Radiation Therapy 
Oncology Group (RTOG) definition.
Our center is equipped with a Cobalt-60 teletherapy 
machine. The International Atomic Energy Agency 
(IAEA) Vienna Austria,  recently  donated  an  HDR 
remote after loader brachytherapy unit   (Gynesource) 
with Co-60 radionuclide source to our center. This 
is  a  replacement  for  our  Caesium-132  low-dose 
rate equipment that was out of use. This machine is 
  manufactured by BEBIG in Germany and it came with 
its Treatment Planning System (TPS)-HDR basic 2.2. 
The brachytherapy suite has a dedicated C-arm X-ray 
machine and all treatment procedures are completed 
within the room without the need to move the patients. 
This HDR brachytherapy unit, the first in Nigeria, 
became functional in July 2008. During the treatment 
of the patients evaluated in this study, the HDR source 
average activity was 60.09 GBq and the Air KERMA 
strength was 17.61 mGym2/hr.
Adjuvant chemotherapy with cisplatin based regi-
men has been shown to improve local control and 
prolong disease progression time in cervical cancer 
patients.3 This approach is still widely used in the 
treatment of cervical cancer.
Objective
To  evaluate  the  acute  gastrointestinal  and  genito-
urinary toxicity following HDR brachytherapy with 
Co-60 radionuclide source.
patients and Methods
Seventy  patients  with  cancer  of  the  uterine  cervix 
who were treated with concurrent chemo   radiotherapy 
at  the  University  College  Hospital  Ibadan  Nigeria 
between July 2008 and March 2009 were selected for 
  evaluation. These were among the first set of patients to 
be treated with HDR brachytherapy with   Co-60 radio-
nuclide source at the center. All the patients had his-
tological confirmation of their diseases; FIGO stages 
included  stages  1  to  111.  Other  selection    criteria 
included  Eastern  Cooperative  Oncology  Group 
(ECOG) performance status of not more than 2, HIV 
sero  negativity  and  haemoglobin  level  of  at  least 
10 mg/dl maintained during the treatment. Tumor size 
measurement was not consistent in all the patients. All 
the patients had teletherapy, brachytherapy with ring 
and tandem applicators and chemotherapy.
radiation therapy
External  beam  radiation  treatment  was  45  Gy  in 
22  daily  fractions  treated  5  days  per  week  over 
4–5  weeks  using  teletherapy  Cobalt  60  machine. 
Antero- posterior and postero-anterior (AP/PA) fields 
were used. A four field box technique was used on 
11  (16%)  patients  with  antero-posterior  diameter 
greater than 18 cm. The superior border of the   pelvic 
field was L4/5 border and the inferior border was at Co-60 hDr source acute toxicity in cervical cancer
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the lower border of the obturator foramen or 2 cm 
below the vaginal extent of the disease. The lateral 
border  was  2  cm  lateral  to  the  widest  true  pelvic 
diameter. On the lateral field, the anterior border was 
placed anterior to the symphysis pubis while the pos-
terior border was placed along the sacrum. Patients 
were treated to mid plane dose on AP/PA fields and at 
isocenter on four field box technique.
High  Dose  Rate  brachytherapy  was  started  not 
  earlier than third week of external beam radiotherapy. 
The dose was 19.5 Gy in 3 weekly fractions. Twice 
a week treatment was allowed given that they were 
separated by at least 72 hours. Conscious sedation of 
patients was used for brachytherapy. Tandem and ring 
applicators were used for all the patients   evaluated. 
A Foley’s catheter was inserted into the urinary   bladder 
and the balloon inflated with 7 cc of diluted Urograf-
fin to identify the bladder neck region.   Barium soaked 
gauze was inserted in the posterior vagina to identify 
rectal point. The vagina was packed with gauze to fur-
ther displace the bladder anteriorly and the rectum pos-
teriorly to minimize the dose to these organs. AP and 
lateral semi orthogonal marker X-rays with the help of 
jig (reconstruction box) were taken with C-arm x ray 
machine at the same place for all insertions and digital 
pictures were obtained. The semi orthogonal pictures 
were reconstructed and treatment planning was done 
with BEBIG HDR basic 2.2. Dose prescription was to 
point “A” (a reference location 2 cm up from cervical 
os point of the uterine tandem and 2 cm lateral to the 
uterine source). Multiple points consistent with ICRU 
38 were located and used for treatment planning and 
dose optimization to point A, point B, bladder, rec-
tum and vaginal surface. A uniform dose of 6.5 Gy 
per fraction was used for all patients during this initial 
experience with the equipment. Bladder and rectum 
doses were optimized to #80% of prescribed point 
A dose. Teletherapy and brachytherapy sessions were 
completed within 8 weeks of patients’ management.
Chemotherapy
All  patients  received  concurrent  chemotherapy. 
  Chemotherapy was usually commenced as soon as pos-
sible after patient’s presentation at the clinic because 
of the long waiting time for radiotherapy and is given 
every 3 weeks to a total of 6 courses. Most patients start 
radiotherapy after second course of   chemotherapy and 
will continue while on   radiotherapy. The   chemotherapy 
regimen included cisplatin 50 mg/m2 given in   infusion 
after  intravenous  (iv)  hydration  and  5  fluoroura-
cil 1 gm/m2 administered as bolus i.v. injection. This 
regimen was adopted in the department when Caesium-
137 low dose brachytherapy was used and was continued 
with the commencement of HDR brachytherapy. Acute 
gastro intestinal and urogenital toxicities were clinically 
assessed weekly during treatment, then 6 weeks and 
every 3 months after treatment using the NCI-Common 
Toxicity   Criteria (NCI-CTC version 4.0). Regular fol-
low up still   continues after this initial evaluation. The 
  assessment of the patients for this report was done within 
90 days of   commencement of treatment.
Results
A total number of 70 patients who met the study cri-
teria were evaluated. All the patients were followed 
up for at least 3 months. The mean age of the patients 
was  45  years  (range  25–69  years).  Three  patients 
were FIGO stage 1, while 24 and 43 patients were 
FIGO stages 11 and 111 respectively. The patient’s 
characteristics are presented in Table 1.
Table 2 shows some of the treatment parameters 
of the patients. Biologically Equivalent Dose (BED) 
calculations were done using the linear quadratic for-
mula assuming an alpha—beta ratio of 10 for tumors 
and 3 for normal tissues.4 The mean BED (Gy10) for 
tumors for both external and HDR radiotherapy was 
86.2 (84.4–88.8) while that for the rectum (Gy3) was 
124.4 (120–133).
Table  3  shows  the  acute  reactions  experienced 
by the patients. Proctitis was the commonest acute 
  reaction  recorded  with  35  (50%)  patients  having 
Table 1. Patients characteristics (n = 70).
Age (years)
Median 45
range 25–69
n %
eCOg performance status
0 52 74
1 15 22
2 3 4
FIgO stage
1B 3 4
11A 9 13
11B 15 22
111A 22 31
111B 21 30ntekim et al
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grade 1 while 5 (7%) had grade 2 proctitis. Diarrhea 
was the second most common acute reaction experi-
enced by the patients with 32 (46%) having grade 1 
while 9 (13%) had grade 2. Grade 3 diarrhea was the 
worst reaction noted among all the patients and this 
occurred in 2 (3%) of the patients. These two patients 
had their treatments disrupted for one week due to the 
toxicity. Genitourinary toxicity were generally mild 
(grade 1) and did not disrupt treatment.
Table 4 describes acute toxicities greater or equal to 
grade 3 in some previous studies of chemo-radiation 
using Ir 192 as HDR radio nuclide source. In our study 
we observed $ grade 3 GI toxicity in 3% of patients. 
Low grade acute toxicities of less than or equal to grade 
2 from the studies in Table 4 are presented in Table 5.
Discussion
The incidence of cancer of the uterine cervix is high 
in  developing  countries  including  Nigeria  where 
about  75%  of  the  patients  present  with  locally 
advanced   disease.5 The combination of external beam 
  radiotherapy and brachytherapy gives high cure rate 
especially with concurrent use of cisplatin based che-
motherapy. HDR brachytherapy has been accepted 
as  standard  method  of  delivering  brachytherapy. 
Cervical cancer is the most common indication for 
brachytherapy  in  most  developing  countries  and 
HDR equipments are capable of treating large num-
ber of patients and hence recommended for develop-
ing countries with high incidence of the disease.6
Iridium-192 is widely used as HDR source and is 
widely  discussed  in  the  literature.  Reports  on  stud-
ies with Cobalt 60 HDR radionuclide source are very 
scanty  especially  with  concomitant  treatment  with 
chemotherapy. All the patients analyzed in this study 
received uniform treatment and the treatment parameters 
were selected to be of benefit to both early and locally 
advanced diseases as well as taking into consideration 
the possible associable normal tissue toxicities. The total 
dose from both external beam and HDR brachytherapy 
in this study was 69.5 Gy with an average BEDGy10 of 
86.2 (84.4–88.8) A total dose range of 65–71 Gy without 
chemotherapy using Ir-192 brachytherapy source has 
been previously prescribed by Jain VS. et al7 with good 
local disease control. A BEDGy10 between 86–109 has 
been shown to result in acceptable pelvic disease con-
trol rate8 though for stage 111 disease, BEDGy10 . 84.5 
was noted to be associated with higher local control and 
5 year survival rates than lower BEDGy10.9 In a report 
by Chen et al10 BEDGy10 range between 82.6 and 101.1 
(median 91.5) was associated with actuarial 5-year over-
all survival of 73% for stage 11B and 56% for stage 111 
diseases and these rates were comparable with other 
studies with similar treatment parameters. The BEDGy10 
of 86.2 (84.4–88.8) obtained in this study would be able 
to achieve comparable results.
An  average  BEDGy3  of  124.4  (120–133)  was 
recorded for rectal point in this study. A rectal BED Gy3 
between 110 and 125 has been shown to be associated 
with acceptable late rectal toxicity rate though with 
lower rate of 12% if #110 and 18% if .110.11
Our results have shown that HDR with Co-60 radio-
nuclide source with concurrent chemotherapy is well 
tolerated in cervical cancer patients. Only 2 patients 
(3%) had grade 3 acute diarrhea that necessitated treat-
ment suspension for one week. There was no grade 3 or 
4 acute genitourinary toxicity among the patients. The 
acute toxicity rates found in this study are among the 
lowest when compared with those reported in studies 
Table 2. Treatment characteristics.
cervical cancer 1B–111B (n = 70) Median Range
external beam radiation 
therapy—whole pelvis (gy)
45 –
high dose rate intracavity 
brachytherapy (gy/fr)
19.5/3 –
Point A biological effective dose 
(BeD) (gy10)
6.5 6.0–7.0
ICrU bladder point (gy3) 5.6 4.2–6.0
ICrU rectal point (gy3) 5.4 3.2–6.0
BeD (gy3) rectum (external + hDr) 124.4 120–133
BeD (gy10) Tumor (external + hDr) 86.2 84.4–88.8
Chemotherapy 3 weekly × 6
  Cisplatin 50 mg/m2 55 50–60
  5-FU 1 gm/m2 1.2 1.0–1.4
Table 3. Acute toxicity during chemo-radiotherapy (n = 70).
Toxicity Grade
0 1 2 3 4
Proctitis 30 (43%) 35 (50%) 5 (7%) 0 0
Diarrhea 27 (38%) 32 (46%) 9 (13%) 2 (3%) 0
nausea 62 (89%) 5 (7%) 3 (4%) 0 0
Vomiting 63 (90%) 5 (7%) 2 (3%) 0 0
Cystitis 42 (60%) 28 (40%) 0 0 0
Urinary  
frequency
40 (60%) 28 (40%) 0 0 0
Urinary  
urgency
40 (60%) 28 (40%) 0 0 0Co-60 hDr source acute toxicity in cervical cancer
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using Ir-192 HDR radionuclide source. In these studies, 
the reported rates of acute toxicity $ grade 3 ranged from 
0%–8% for gastrointestinal and 0%–3% for genitouri-
nary toxicities (Table 4). Other studies with low –dose 
rate brachytherapy reported acute toxicity $ grade 3 
range from 0%–15% for gastrointestinal and 1%–8% 
for genitourinary toxicities. It was also observed that 
the influence of chemotherapy regimen on gastrointes-
tinal and genitourinary toxicities was less apparent.12 
The  early  (#grade  2)  gastrointestinal  and  genitouri-
nary toxicities experienced by patients in this study are 
similar to outcomes from other studies though compari-
son is difficult because most authors ignore these mild 
symptoms hence they are not reported and if reported, 
consistent scoring criteria are not used (Table 5).
The acute genito-urinary toxicity in this study is 
relatively low though the risk of late treatment related 
toxicity  is  yet  to  be  evaluated  but  this,  together 
with effectiveness of treatment, are expected to be 
similar to previous reports. In a 20 year retrospec-
tive analysis of Co-60 HDR brachytherapy in Iran, 
  Mosalaei A. et al13 reported a 10-year overall and dis-
ease free survival rate of 62.4% with about 6% severe 
  genito-  urinary  and/or  gastrointestinal  toxicity.  In 
that analysis, a uniform external beam dose of 50 Gy 
in 5–5.5 weeks using Co-60 machine was used and 
brachytherapy was 30 Gy in 3 fractions using Co-60 
remote after-loading equipment. Treatment planning 
was done manually and chemotherapy was not given. 
These were assessed to be comparable with reported 
brachytherapy results in the literature.
As this initial evaluation of HDR brachytherapy 
practice in our centre with other studies are favor-
able,  the  use  of  adjusted  treatment  schedules  with 
differential  radiotherapy  doses  for  early  and  late 
stage  diseases  as  recommended  by  the  American 
Brachytherapy Society and adopted in some earlier 
reports using Ir-192 HDR source14,15 could be adopted 
for Co-60 radionuclide. In the adjustment treatment 
schedules, chemotherapy regimen would be changed 
to weekly cisplatin with a dose range of 25–30 mg/m2, 
as this has been shown to be more tolerable and equally 
effective when compared with 40 mg/m2 dosage. The 
use of 5-fluorouracil would also be   discontinued as it 
Table 4. Comparison of $grade 3 gI and gU acute toxicities in previous studies of chemo-radiation using Ir 192 as hDr 
source.
study Radiotherapy Gy/fr GI toxicity GU toxicity
Regimen ext HDR % %
Chung Y et al 2005 4 weekly CP 45/25 25/5 2 0
Chen s et al 2006 Weekly CP 45/25 24/4 4.3 0
nyongesa C et al 2006 Weekly CP 46/23 26/4 0 0
shakespeare et al 2006 Weekly CP 45/25 31.8/6 0 0
Kim Y et al 2008
  group 1 4 weekly CP/5FU 41.4/23 30/6 8 3
  group 2 Weekly CP 41.4/23 30/6 0 0
Current study (with Co-60) 4 weekly CP/5FU 45/22 19.5/6 3 0
Abbreviations: Ext, External beam radiotherapy; GI, gastro intestinal; GU, genitourinary; CP, cisplatin; 5FU, 5- fluorouracil.
Table 5. Comparison of some early (#grade 2) gI and gU acute toxicities in the previous studies cited in Table 4.
study Toxicity (%)
proctitis Diarrhea nausea Vomiting cystitis GU GI
Chung Y et al 200515 – 77 44 – – 22 –
Chen s et al 200610 – – – – – 5.7 51.4
nyongesa C et al 200616 – 58 92 58 – – –
shakespeare et al 20063 4.8 – – – 23.8 – 47.6
Kim Y et al 200817
  group 1 – – – – – 10 26
  group 2 – – – – – 9 26
Current study (with Co-60) 57 59 11 10 – 40 –publish with Libertas Academica and 
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has been shown to be of no added advantage to the 
treatment outcome but rather leads to increased acute 
hematological toxicity.16,17
conclusion
This study shows that acute gastrointestinal and genito-
urinary toxicity following high-dose-rate brachyther-
apy with Co-60 radionuclide source in chemoradiation 
treatment of cervical cancer is low and comparable with 
those reported for Iridium-192 HDR source. Cobalt 60 
has lots of economic advantages over Ir-192 and hence 
suitable for low resource radiotherapy settings.
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